New York, USA – October 19, 2020 – As of 14 October 2020, COVID-19 is affecting 214 countries and territories around the world with more than 38 million cases confirmed and over 1 million deaths. According to Johns Hopkins University, the US is still averaging over 49,000 new infections every day, which indicates that effective and safe vaccines or antiviral drugs are in urgent need.
Creative Biolabs, a biotechnology company that has conducted extensive and in-depth research on the MERS epidemic in 2012, now is dedicated to helping global scientists with their drug discovery and vaccine development. The senior scientists at Creative Biolabs are devoted to extending the range of first-class antiviral drug discovery services, and has updated SARS-CoV-2 neutralizing antibody development service, as well as nucleoside analogue discovery service.
• Nucleoside Analogue for the Treatment of SARS-CoV-2
Nucleoside analogue inhibitors are chemically synthesized analogues of purines and pyrimidines in which the heterocyclic ring or sugar moiety has been altered and includes 5-substituted 2′-deoxyuridine analogs. Nucleoside analogue has presented a possibility in the treatment of COVID-19.
“According to previous research, gemcitabine hydrochloride has been demonstrated that gemcitabine hydrochloride inhibits both MERS-CoV and SARS-CoV with low toxicity, so we offer professional service in the validation of gemcitabine hydrochloride for SARS-CoV-2, hoping to facilitate rapid responses to this infectious disease.”
Creative Biolabs provides comprehensive R&D services of antiviral nucleoside analogues based on multiple action mechanisms, covering Ribavirin, Remdesivir, BCX4430, Acyclovir Fleximer, etc.
• Neutralizing Antibody Development for SARS-CoV-2
Neutralizing antibodies (nAbs) are major contributors to protect responses against most viral invaders. With years of exploration in coronaviruses and antibodies, an expert team has been organized at Creative Biolabs for the research of ongoing SARS-CoV-2 infection and to develop multiple neutralizing antibodies.
Creative Biolabs provides therapeutic human monoclonal antibody screening services from COVID-19 recovered patient sera via its advantage in antibody discovery, and the service of immunizing humanized antibody mice with SARS-CoV-2 surface protein to screen for therapeutic human monoclonal antibodies.
The portfolio of antiviral drug discovery at Creative Biolabs also covers services on SARS-CoV-2 aptamers, protease inhibitors, antiviral peptide, high-throughput screening, etc. In addition, Creative Biolabs is also experienced in vaccine discovery, including but not limited to SARS-CoV-2 live attenuated and killed vaccine, mRNA vaccine, in silico vaccine, DNA vaccine, and evaluation platforms for neutralization assay, protease inhibitor assay, etc.
More information can be found on https://sars-cov-2.creative-biolabs.com.
About Creative Biolabs
Empowered by leading technology and over 15 years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.